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Background: The aim of the present study was to compare circulating levels of selected prothrombotic markers in
patients suffering acute myocardial infarction (AMI) with and without left ventricular (LV) thrombus.
Methods: One hundred patients with AMI treated with PCI on the LAD and dual antiplatelet therapy were
included. LV thrombus formation was detected by echocardiography and/or MRI in 15 patients. Fasting blood
samples were drawn 4–5 days (baseline), 6–7 days, 8–9 days, 2–3 weeks and 3 months after the AMI for
determination of haemostatic markers.
Results: We found higher levels of soluble tissue factor (TF) and D-dimer in the LV thrombus group 4–5 days, 8–9
days and 3 months (only TF) after the AMI compared to the patients without thrombus formation (p<0.05). Patients
with TF in the upper quartile at baseline had significantly higher risk for LV thrombus (OR 4.2; 95% CI 1.2 -14.5;
p=0.02, adjusted for infarct size).
The levels of prothrombin fragment 1+2 (F1+2) and endogenous thrombin potential (ETP) were significantly lower
in the thrombus group after 8–9 days (only ETP), 2–3 weeks and 3 months. The levels of plasminogen activator
inhibitor 1 activity and tissue plasminogen activator antigen did not differ between the groups.
Conclusion: In the acute phase of AMI, we found higher levels of TF and D-dimer in the LV thrombus group,
indicating hypercoagulability of possible importance for the generation of mural thrombus. Lower levels of F1+2,
ETP and D-dimer in the thrombus group late during follow-up are probably induced by the initiated
anticoagulation therapy.
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Left ventricular (LV) thrombus formation is a serious
complication in patients with acute myocardial infarction
and was reported in up to 60% of patients with acute an-
terior wall myocardial infarction before thrombolytic treat-
ment was introduced [1,2]. In the percutaneous coronary
intervention (PCI) era studies have shown that LV
thrombus formation still occurs in patients with anterior* Correspondence: s-solh@online.no
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reproduction in any medium, provided the orwall myocardial infarction [3-6]. The exact mechanism for
the development of mural thrombosis is not elucidated,
but abnormal blood flow with stasis, endocardial injury
with an inflammatory response and hypercoagulability are
probably all involved.
The aim of the present study was to determine the cir-
culating levels of prothrombotic markers in patients suf-
fering acute anterior wall myocardial infarction with and
without mural thrombosis, all treated with PCI and dual
antiplatelet therapy. In addition, we wanted to examine
any association between haemostatic variables and mar-
kers of inflammation.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Materials
The study design, patients demographics and inclusion
and exclusion criteria have been published in detail
previously [5]. Briefly, one hundred patients with acute an-
terior wall ST-elevation myocardial infarction, both gen-
der, age between 40 and 75 years were included at Ullevål
University Hospital and Rikshospitalet University Hospital,
Oslo, Norway. All the patients participated in the
ASTAMI (Autologous Stem cell Transplantation in Acute
Myocardial Infarction) trial with the culprit lesion located
in the left anterior descending artery (LAD), proximal to
the 2. diagonal branch, and were treated successfully with
PCI and stent implantation within 2 – 12 hours from
symptom start, in addition to dual antiplatelet therapy [7].
The inclusion criteria were peak creatine kinase (CK) MB
above 3 times the upper reference level and hypo- or akin-
esia in more than 2 of 16 segments of the left ventricle
determined by echocardiography. Patients with cardiogenic
shock, previous Q-wave infarction and considerable
co-morbidity with short life expectancy were excluded
from the study. The investigation conformed with the prin-
ciples outlined in the Declaration of Helsinki. The Regional
Committee for Medical Research Ethics approved the
study protocol, and written informed consent was obtained
from all the patients. The present study is a substudy of
the ASTAMI trial that is registered at www.clinicaltrials.
gov, NCT 00199823.
Methods
The included patients were randomized 1:1 to receive
intracoronary injections of autologous mononuclear bone
marrow cells (mBMC) or to a control group without any
further interventions. The mBMC group was aspirated for
50 ml bone marrow from the iliac crest in local anesthesia
4 – 7 days after the acute PCI and the next day, a median
of 6 days after the AMI, they received intracoronary injec-
tions of mBMC in the LAD. All the patients were treated
with a loading dose of clopidogrel 300 mg and thereafter
75 mg daily in addition to an initial dose of aspirin 300 mg
followed by 75 mg daily. Patients with LV thrombus were
treated with low molecular weight heparin and further
warfarin with a target international normalized ratio of 2.0
to 2.5 for at least 3–6 months. Fasting blood samples were
drawn 4–5 days (baseline), 6–7 days, 8–9 days, 2–3 weeks
and 3 months after the AMI for determination of circulat-
ing haemostatic markers and selected inflammatory med-
iators (only at baseline). In accordance with the study
protocol a screening echocardiographic examination of all
eligible patients was performed within the first 1–3 days
after the acute PCI. Thereafter, echocardiograms were
obtained by Vivid 7 scanner (GE Vingmed Ultrasound,
Horten, Norway) of all the included patients 4.5 ± 1.1
days after the acute AMI and repeated after 3 months.Additional echocardiographic examinations were per-
formed in between the predefined time points when
clinically indicated. Magnetic resonance imaging (MRI)
was performed with a 1.5-tesla scanner (Siemens, Germany)
18.8 ± 4.3 days after the acute PCI. Infarct size of the LAD
area, in percent, was obtained by electrocardiogram-gated
single photon emission computed tomography (SPECT) (GE
Medical Systems with 4D-MSPECT software) 4.0 ± 1.4 days
after the AMI.
Enzyme immunoassays
Soluble tissue factor (TF) was measured by an enzyme-
linked immunoassay (ImubindW Tissue Factor, American
Diagnostica Inc., US), prothrombin fragment 1+2 (F1+2)
by an enzyme immunoassay (EnzygnostWF1+2, Siemens
Healthcare Diagnostics, Marburg, Germany). Endogenous
thrombin potential (ETP) was determined according to
the manufacturer’s instruction (Thrombinoscope BV,
Maastricht, The Netherlands) and the thrombin generation
was measured on the Fluoroscan AscentW fluorometer
(Thermo Fisher Scientific OY, Vantaa, Finland). A reagent
of rTF and phospholipids in addition to a thrombin spe-
cific fluorogenic substrate (Z-Gly-Gly-Arg-AMC, Bachem,
Bubendorf, Switzerland) in Hepes buffer containg CaCl2,
were added to the plasma prior to start to obtain a final
concentration of 5 pM, 4 uM and 2.5 mM, respectively. In
order to calculate the final results, plasma was analyzed
along with a thrombin calibrator with known thrombin ac-
tivity as a reference. The software program (Thrombino-
scope BV, version 3.0.0.29) enabled the calculation of ETP.
All the experiments were run in duplicates. D-dimer was
measured by enzyme immunoassay (Asserachrom, D-di™,
Stago Diagnostica, Asniere, France) and plasminogen acti-
vator inhibitor 1 (PAI-1) activity by a bio immunoassay
(Trinilize PAI-1 activity, Trinity Biotech, plc, Bray, Co.
Wicklow, Ireland). The levels of tissue plasminogen activa-
tor (tPA) antigen were determined by enzyme immuno-
assay (TintElizeWtPA, Trinity Biotech, Jamestown, NY,
US). Tumor necrosis factor α (TNFα) and interleukin 6
(IL-6) were measured by enzyme immunoassays obtained
from R&D Systems Europe (Abingdon, Oxon, UK).
C-Reactive protein (CRP) was determined by an enzyme-
linked immunosorbent assay (DRG Instruments GmbH,
Germany) (detection limit 0.1 mg/L). In our laboratory,
the interassay coefficient of variation for TF was 4.4%; F1
+2 7.8%; ETP 2.7%; D-dimer 6.5%; PAI-1 4.4%; tPA 3.5%;
TNFα 8,5%; IL-6 10.7%; CRP<5%.
Gene expression
Total RNA was extracted from PAXgeneW Blood RNA
tubes in a subset of patients with (n=7) and without (n=10)
LV thrombus. The PAXgeneW Blood RNA Kit (PreAnalytix,
Qiagen GmbH, Germany), including an extra cleaning step
(RNeasyWMinEluteW Cleanup Kit, Qiagen) was used. Total
Table 1 General characteristics of the patients with and
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using the OmniscriptW RT Kit (Qiagen), Oligos (dTs) and
Rnase Inhibitor (Applied Biosystems, Foster City, CA,
USA). TF mRNA levels were determined by real-time PCR
on the ABI Prism 7900 HT Sequence Detection System,
including the TaqManW Gene Expression TF Assay
(Hs01076029_m1). The TF mRNA levels were normalized
to β-2-microglobulin (Hs99999907_m1, Applied Biosys-
tems) and fold expression (relative quantification using the
ΔΔCt method) was determined in relation to a reference
sample, as previously described [8].
Statistical analysis
Variables are expressed as proportions, medians with
25,75 percentiles or means with standard deviation as ap-
propriate. Differences between groups were analysed with
the Mann–Whitney test for continuous variables. Categor-
ical data were analyzed by the chi-square test. Friedman
test was applied for testing the intragroup differences be-
tween several related samples and Wilcoxon test was used
when Friedman test was significant, to assess within group
changes from baseline to the subsequent time points. A
trend analysis in quartiles of variables was performed by
the chi square test to estimate the cut off levels in relation
to LV thrombus. Logistic regression analyses with LV
thrombus as the dependent variable were performed with
adjustments for infarct size. Correlation analysis was done
with Spearmans rho. All tests were two-sided, and p values
<0.05 were considered statistically significant. PASW soft-
ware package version 18.0 for Mac OS X was used for data






Age (years) 57(50,64) 63(50,69) 0.18
Female 15(18%) 1(7%) 0.49
Current smoker 37(44%) 7(47%) 0.20
Hypertension 27(32%) 7(47%) 0.41
Hyperlipidemia 39(46%) 9(60%) 0.47




























Hypertension is defined as antihypertensive treatment or measured blood
pressure above 140/90 mmHg. Hyperlipidemia is defined as baseline fasting
total cholesterol above 5.5 mmol/L or previous use of cholesterol lowering
medication. P-values refer to differences between the LV thrombus group and
those without thrombus formation. CK; creatine kinase, LAD; the left anterior
descending artery, SPECT; single photon emission computer tomography.Results
General characteristics
Primary PCI was performed in 71 patients, facilitated PCI
in 15 patients and rescue PCI in 14 patients without any
differences between the groups. As previously described,
we detected LV thrombus formation in 15 of 100 patients
within the first 3 months, most of them diagnosed during
the first week after the AMI [5]. LV thrombus formation
was diagnosed by echocardiography in 13 patients and by
MRI in 2 patients. No between group differences in base-
line characteristics was found, except from significantly
higher peak CK levels and larger infarct size assessed by




The levels of TF were significantly higher in the LV
thrombus group 4–5 days, 8–9 days and 3 months after
the AMI compared to the patients without thrombus for-
mation (Figure 1, Panel A). In both groups, the TF levelsdeclined significantly from day 4–5 to day 6–7, 8–9 and 2–
3 weeks. Only in the thrombus group we found a small,
but significant increase of TF levels from day 4–5 to 3
months. Trend analysis through quartiles of TF showed in-
creasing numbers of LV thrombus with increasing levels of
TF measured 4–5 days after the AMI. Patients with base-
line TF levels in the upper quartile (≥167.8 ng/ml) had sig-
nificantly higher risk for LV thrombus, with an odds ratio
of 4.2 (95% confidence interval 1.5-14.4; p = 0.01), adjusted
for infarct size assessed by SPECT 4–5 days after the AMI.
Tissue factor mRNA expression
The TF mRNA expressions were numerically higher in the
LV thrombus group within the first 6–7 days after the
AMI, however, not statistically significant (p>0.3 for all
time points) (Figure 2). At later time points no between
group differences were detected in the mRNA levels of TF.
Prothrombin fragment 1+2
A different pattern could be demonstrated for F1+2, with
significantly lower levels in the thrombus group after 2–3
weeks and 3 months (p<0.01) (Figure 1, Panel B). In both
groups, the F1+2 levels declined from 4–5 days to later
time points.
Endogenous thrombin potential
A similar pattern as for F1+2 was found for ETP, with sig-
nificantly lower levels in the thrombus group 8–9 days,
Figure 1 Circulating levels of tissue factor, F1+2, D-dimer, PAI-1 activity, tPA antigen and ex vivo ETP measured 4–5 days, 6–7 days,
8–9 days, 2–3 weeks and 3 months after the AMI. Median values with 25th, 75th percentiles are given. § refers to p-value < 0.05 for
differences between the groups at the various time points, and * indicates p-value <0.05 for intragroup differences from day 4–5 to the
subsequent time points. F1+2; prothrombin fragment 1+2, ETP; endogenous thrombin potential, PAI-1; plasminogen activator inhibitor 1 activity,
tPA; tissue plasminogen activator antigen.
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in both groups from day 4–5 to day 8–9 and later on
(Figure 1, Panel C).
D-dimer
The levels of D-dimer were significantly higher in the
thrombus group at all time points except at 3 months
where lower levels were obtained in the thrombus group
(Figure 1, Panel D). In both groups the levels declined, but
significantly only from day 4–5 to 2–3 weeks and 3
months. Patients with baseline D-dimer levels in the upper
quartile (≥1960 ng/ml) had significantly higher risk for LV
thrombus with an odds ratio of 3.8 (95% CI 1.1-13.0;Figure 2 The expression of mRNA TF in peripheral whole blood
related to a reference sample at the various time points in the
two groups. TF; tissue factor.p=0.03), adjusted for infarct size determined by SPECT 4–5
days after the AMI.Tissue plasminogen activator antigen and plasminogen
activator inhibitor 1 activity
No significant between group differences could be detected
regarding the levels of tPA antigen and PAI-1 activity
(Figure 1, Panel E and F). Only a minor reduction of the
tPA levels from 4–5 days to 3 months could be demon-
strated in the thrombus group and a small, but statistically
significant increase of PAI-1 from day 4–5 to 2–3 weeks
and 3 months in patients without thrombus formation.Circulating levels of selected inflammatory markers at
baseline
The median levels of TNFα, IL-6 and CRP at baseline
were numerically higher in the thrombus group versus
those without LV thrombus, but not statistically significant
(2.13 versus 1.89 pg/ml, p=0.57; 7.77 versus 7.63 pg/ml,
p=0.49; 19.70 versus 16.39 mg/L, p=0.27).Correlation between TF and selected inflammatory
mediators at baseline in the LV thrombus group
There was a significant correlation between the levels of
TF and TNFα measured 4–5 days after the AMI with a
coefficient of correlation of 0.55 (p=0.03), but not for IL-6
and CRP.
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In the acute phase of AMI, we found significantly higher
circulating levels of TF and D-dimer in the LV thrombus
group, indicating hypercoagulability which might be of im-
portance for the generation of mural thrombus. We have
recently published that the patients with larger infarct size,
evaluated with peak CK levels, had significantly increased
risk for LV thrombus formation [5]. Larger infarct size is,
undoubtedly, associated with increased risk for LV
thrombus formation as shown in several studies [3,6,9-11].
In the present study we found, even after adjustment for
infarct size, that high levels of TF and D-dimer, measured
4–5 days after the AMI, were associated with increased
risk for LV thrombus with an odds ratio of 4.2 (1.5-14.4)
and 3.8 (1.1-13.0), respectively. These findings may indicate
that increased expression of TF plays a key role in the gen-
esis of LV thrombus formation. Furthermore, the expres-
sion levels of TF mRNA in whole blood were higher in the
thrombus group, although not statistically significant,
probably due to limited numbers in these analyses. The
higher D-dimer levels in the LV thrombus group are prob-
ably induced by increased thrombin generation and fibrin
formation indicating increased procoagulant activity.
Interestingely, we also found a strong correlation be-
tween the levels of circulating TF and TNFα, that indicates
an association between inflammatory responses and hyper-
coagulability in these patients. Several coagulant mediators
are also proinflammatory [12]. Porreca et al. have shown a
significant positive association between the levels of TF
and CRP in hypercholesterolemic subjects [13]. Animal
models have shown that TF may induce inflammatory
artrithis with increased levels of IL-6 probably through a
thrombin dependent pathway where both fibrin formation
and platelet activation mediated by the receptor PAR-4, are
essential [14]. On the other hand, inflammatory mediators
themselves may also trigger coagulation. Kambas and cow-
orkers suggest that TNFα is involved in the upregulation of
TF in patients with acute respiratory distress syndrome
[15]. These findings support our suggestion that co-
activation of coagulation and inflammation plays a central
in the formation of LV thrombus in the present population.
Late during follow up, we found lower levels of F1+2
and ETP in patients with LV thrombus compared to the
non-thrombus group. This is probably because of ongoing
anticoagulation therapy in these patients and thereby less
thrombin generation. Higher levels of TF at 3 months in
the LV thrombus group may be related to ongoing treat-
ment with warfarin and less consumption of TF as previ-
ously reported [16]. In our study, we also found that
several prothrombotic markers decreased after 2–3 weeks
and 3 months in both groups indicating less hypercoagul-
ability late during follow up after the AMI, which is in line
with other studies [17]. Several clinical trials have also
shown that increased levels of prothrombotic markers inAMI patients are associated with worse outcome [18-20].
In the present study, all patients were alive after 1 year with
few non-fatal cardiovascular events, and any association
between increased levels of prothrombotic markers and
clinical outcome has therefore not been examined.
Conclusion
Our findings indicate that hypercoagulability along with
large infarct size and probably proinflammatory activity
are key factors in the genesis of LV thrombus formation
in patients with AMI treated with dual antiplatelet medi-
cation with limited effect on the coagulation system. The
decline in procoagulant activity later on after the AMI,
most pronounced in the LV thrombus group, is probably
caused by ongoing anticoagulation therapy. Patients with
large anterior wall myocardial infarction and high levels of
TF and D-dimer have increased risk for LV thrombus
formation and should be considered for anticoagulation
therapy.
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